---
document_datetime: 2023-09-21 19:33:15
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/fuzeon-epar-all-authorised-presentations_en.pdf
document_name: fuzeon-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.73001
conversion_datetime: 2025-12-29 20:02:26.538586
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| <EMA procedure number> <MA (EU) number>   | (Invented) name   | Strength   | Pharmaceutical form                           | Route of administration   | Immediate Packaging                         | <Content (concentration)>    | Pack size                                                                                    |
|-------------------------------------------|-------------------|------------|-----------------------------------------------|---------------------------|---------------------------------------------|------------------------------|----------------------------------------------------------------------------------------------|
| EU/1/03/252/001                           | Fuzeon            | 90 mg/ml   | Powder and solvent for solution for injection | Subcutaneous use          | powder: vial (glass); solvent: vial (glass) | powder: 90 mg; solvent: 2 ml | 60 vials powder + 60 vials solvent + 60 3 ml syringes + 60 1 ml syringes + 180 alcohol swabs |